EM2209C "Medical Therapies to Improve CV and Renal Outcomes in Patients with T2D and ASCVD: State of the Art in 2022" (IM GR-090922)
Purpose and Overview
To review the evidence base supporting currently underused medical treatments shown to improve cardiovascular and renal outcomes in people with Type 2 Diabetes Mellitus and established atherosclerotic cardiovascular disease. To provide practicing clinicians with clear and easily applied guidance on medical management of these patients to the current optimal standard.
Target Audience
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Understand the role of lipid modifying therapies beyond statins in people with T2D and ASCVD.
- Understand the evidence base and clinical role of medications (SGLT2 inhibitors and GLP-1 receptor agonists) proven to improve cardiovascular and renal outcomes in diabetes cardiovascular outcomes trials.
- Understand the indications and use case for the nonsteroidal mineralocorticoid, finerenone, in patients with T2D, ASCVD, and CKD.
Sandeep Das, M.D., M.P.H.
Professor of Internal Medicine
Service Chief, Cardiology
Medical Director, Acute Coronary Service at Parkland Program
Director, Quality Officer at CUH
Available Credit
- 1.00 AMA
- 1.00 Attendance
Price
Required Hardware/software
Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome